Epigallocatechin‐3‐gallate induces telomere shortening and clastogenic damage in glioblastoma cells. (10th May 2019)

• Record Type: Journal Article
• Authors: Udroiu, Ion; Marinaccio, Jessica; Sgura, Antonella
• Is Part Of: Environmental and molecular mutagenesis. Volume 60:Number 8(2019)
• Page Start: 683
• Page End: 692
• Publication Date: 2019-05-10
• Subjects: telomerase -- senescence -- DNA damage -- flavonoid -- inhibitor; Mutagenesis -- Periodicals; Molecular genetics -- Periodicals; Mutagenèse -- Périodiques; Mutagenèse chimique -- Périodiques; Mutation -- Périodiques; Maladies de l'environnement -- Périodiques; Génétique moléculaire -- Périodiques; 576.542
• DOI: 10.1002/em.22295
• Languages: English
• ISSNs: 0893-6692

Abstract

Abstract : Epigallocatechingallate (EGCG) is the major polyphenol in green tea, to which many anticancer features, such as antioxidative, antigenotoxic, and antiangiogenetic properties, are attributed. Moreover, it is also well known as a telomerase inhibitor. In this work, we have chronically treated U251 glioblastoma cells with low, physiologically realistic concentrations, of EGCG, in order to investigate its effects both on telomeres and on genome integrity. Inhibition of telomerase activity caused telomere shortening, ultimately leading to senescence and telomere dysfunction at 98 days. Remarkably, we have observed DNA damage through an increase of phosphorylation of γ‐H2AX histone and micronuclei also with doses and at timepoints when telomere shortening was not present. Therefore, we concluded that this DNA damage was not correlated with telomere shortening and that EGCG treatment induced not only an increase of telomere‐shortening‐induced senescence but also telomere‐independent genotoxicity. This study questions the common knowledge about EGCG properties, but confirms the few works that indicated the clastogenic properties of this molecule, probably due to DNA reductive damage and topoisomerase II poisoning. Environ. Mol. Mutagen., 60:683–692, 2019. © 2019 Wiley Periodicals, Inc.